Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1
The prognostic and/or predictive value of the cancer biomarkers, urokinase-type plasminogen activator (uPA) and its inhibitor (plasminogen activator inhibitor [PAI]-1), determined by ELISA in tumor-tissue extracts, was demonstrated for several cancer types in numerous clinically relevant retrospective or prospective studies, including a multicenter breast cancer therapy trial (Chemo-N0). Consequently, for the first time ever for any cancer biomarker for breast cancer, uPA and PAI-1 have reached the highest level of evidence, level-of-evidence-1. At present, two other breast cancer therapy trials, NNBC-3 and Plan B, also incorporating uPA and PAI-1 as treatment-assignment tools are in effect. Furthermore, small synthetic molecules targeting uPA are currently in Phase II clinical trials in patients afflicted with advanced cancer of the ovary, breast or pancreas.
|Keywords||clinical utility, individualized tailored cancer care, personalized cancer treatment, predictive impact, prognostic relevance, prospective clinical trial, retrospective clinical study, targeted therapy|
|Persistent URL||dx.doi.org/10.1586/erm.10.71, hdl.handle.net/1765/33015|
Schmitt, M., Mengele, K., Napieralski, R., Magdolen, V., Reuning, U., Gkazepis, A., … Harbeck, N.. (2010). Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Review of Molecular Diagnostics, 10(8), 1051–1067. doi:10.1586/erm.10.71